ClinicalTrials.gg

Program

EP4 Receptor Antagonist YY001

Also written as “Rcombinant botulinum neurotoxin type A for injection (YY001)”, “YY001” and “Recombinant botulinum toxin type A for injection (YY001)”.

Its studies are led by 2 companies.

Furthest: phase 3, since Jul 7, 20246 company-led studies, 2 open or runningNext primary completion: Jun 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Claruvis Pharmaceutical52 open or runningphase 3since Jul 7, 2024Feb 15, 2023Jun 1, 2027phase 3 · NCT07478822
Shanghai Yuyao Biotech10 open or runningphase 1since Jan 17, 2024Jan 17, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 15, 2023First study: phase 2 study in Moderate to Severe Glabellar LinesNew to Chongqing Claruvis PharmaceuticalChongqing Claruvis Pharmaceutical · NCT05743634 · 140 enrolled · China
  2. Jan 17, 2024Shanghai Yuyao Biotech’s first study: phase 1 study in Advanced Solid TumorNew to Shanghai Yuyao BiotechShanghai Yuyao Biotech · NCT06228846 · 16 enrolled · China
  3. Jul 7, 20242 phase 3 studies in Moderate to Severe Glabellar LinesChongqing Claruvis Pharmaceutical · NCT06583486, NCT06499688
  4. Jan 14, 2025Phase 3 study in Upper Limb SpasticityChongqing Claruvis Pharmaceutical · NCT06783114 · 254 planned · China
  5. Mar 11, 2026Phase 3 study in Upper Limb SpasticityChongqing Claruvis Pharmaceutical · NCT07478822 · 300 planned · China

Ahead

  1. Jun 1, 2027Primary completion: phase 3 study in Upper Limb SpasticityChongqing Claruvis Pharmaceutical · NCT07478822

TargetBeta

PTGER4 →read by rule
“An orally bioavailable small molecule antagonist of the prostaglandin E2 receptor EP4 subtype (PTGER4; EP4), ”NCIt, by rule

Other programs on PTGER4

ProgramCompanyFurthest phaseStudies
BMS-986310ruleOno Pharmaceuticalphase 36
EP2/EP4/DP1 Antagonist OKN4395ruleepkinphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07478822Upper Limb Spasticity · China3RecruitingChongqing Claruvis PharmaceuticalJun 1, 2027300
NCT06783114Upper Limb Spasticity · China3RecruitingChongqing Claruvis PharmaceuticalSep 30, 2026254
NCT06583486Moderate to Severe Glabellar Lines · China3CompletedChongqing Claruvis PharmaceuticalAug 25, 2025488
NCT06499688Moderate to Severe Glabellar Lines · China3CompletedChongqing Claruvis PharmaceuticalMar 29, 2024529
NCT06228846Advanced Solid Tumor · China1CompletedShanghai Yuyao BiotechApr 30, 202416
NCT05743634Moderate to Severe Glabellar Lines · China2CompletedChongqing Claruvis PharmaceuticalFeb 13, 2023140

How it is read

Names in the registry

  • “Rcombinant botulinum neurotoxin type A for injection (YY001)”, 2 entries
  • “YY001”, 2 entries
  • “Recombinant botulinum toxin type A for injection (YY001)”, 1 entry
  • “Recombinant Botulinum Toxin Type A for injection (YY001)”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.